Liquid biopsy is transforming lymphoma diagnosis and monitoring by analyzing circulating tumor DNA (ctDNA) from blood instead of traditional tissue biopsies. This approach enables early detection and helps track treatment response. For example, EBV DNA can be detected in T-cell lymphoma, and AI can enhance monitoring in follicular lymphoma, offering more precise insights into disease progression.
Advanced imaging techniques, such as PET/CT scans with measurements like Metabolic Tumor Volume (MTV), improve predictions of treatment response. Machine learning and AI further enhance analysis by integrating imaging and liquid biopsy data, providing more accurate diagnostic and prognostic assessments.
Ongoing research and guideline updates from organizations like the European Hematology Association and the Lymphoma Research Foundation are refining treatment strategies for specific lymphoma subtypes, including marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL). Together, these advances make lymphoma care more personalized, precise, and less invasive.